Yu-Sen Peng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yu-Sen Peng has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Hon-Yen Wu
Division of Nephrology, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan
7 shared publications - Ju-Yeh Yang
Division of Nephrology, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan
5 shared publications - Shih-Ping Hsu
Department of Medical Education, Far Eastern Memorial Hospital, New Taipei City, Taiwan
5 shared publications - Wan-Chuan Tsai
Division of Nephrology, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan
5 shared publications - Yen-Ling Chiu
Graduate Institute of Medicine, Yuan-Ze University, Taiwan
4 shared publications - Chih-Kang Chiang
Graduate Institute of Toxicology, College of Medicine, National Taiwan University, Taipei 100233, Taiwan
3 shared publications
Latest Publications
- Open Access
- 2 July 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (10) , 2303-2312
Nonclassical Monocyte Expansion Is Independently Associated with Anemia Severity in Patients with ESKD
Key Points: Nonclassical monocyte expansion is independently associated with lower hemoglobin in patients on hemodialysis after multivariable adjustment. This monocyte–anemia association is independent of systemic inflammation but linked to altered iron homeostasis markers. The association is the strongest in diabetic patients, suggesting that monocyte profiling may identify nontraditional anemia risk. Background: Anemia remains a major contributor to morbidity and mortality in patients treated by hemodialysis despite current anemia management strategies. Nonclassical monocytes (CD14 + CD16 ++ ), which expand in ESKD and participate in iron recycling through heme scavenging, represent an unexplored link to anemia in this population. Methods: In this two-center, cross-sectional analysis of 408 patients treated by prevalent hemodialysis from the prospective Immunity in End-Stage Renal Disease (iESRD) cohort, monocyte subsets were quantified by multicolor flow cytometry. Associations between nonclassical monocyte percentage (%M3) and hemoglobin were evaluated using Spearman rank correlations and multivariable linear regression adjusted for demographics, dialysis vintage, erythropoietin dose, iron parameters, inflammatory markers, and comorbidities. Results: The mean age was 62±12 years, 57% were male, and 45% had diabetes. Patients in the highest %M3 tertile had lower hemoglobin than those in the lowest tertile (10.6±1.2 versus 11.1±1.6 g/dl; P = 0.01). In multivariable regression, each one-tertile higher %M3 was independently associated with 0.29 g/dl lower hemoglobin ( β =−0.29; 95% confidence interval, −0.43 to −0.15; P < 0.001), and this association persisted after further adjustment for BUN and serum creatinine ( β =−0.31; P < 0.001). The association was not attenuated by adjustment for high-sensitivity C-reactive protein, and %M3 showed no correlation with IL-6 or TNF- α . The association was the strongest among diabetic patients (ρ=−0.27; P < 0.001). Conclusions: Nonclassical monocyte expansion is independently associated with anemia severity in patients treated by hemodialysis through an inflammation-independent pathway involving altered iron homeostasis. Monocyte subset profiling may identify patients at risk of refractory anemia.
- 2 July 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (10) , 2303-2312
Open AccessNonclassical Monocyte Expansion Is Independently Associated with Anemia Severity in Patients with ESKD
Key Points: Nonclassical monocyte expansion is independently associated with lower hemoglobin in patients on hemodialysis after multivariable adjustment. This monocyte–anemia association is independent of systemic inflammation but linked to altered iron homeostasis markers. The association is the strongest in diabetic patients, suggesting that monocyte profiling may identify nontraditional anemia risk. Background: Anemia remains a major contributor to morbidity and mortality in patients treated by hemodialysis despite current anemia management strategies. Nonclassical monocytes (CD14 + CD16 ++ ), which expand in ESKD and participate in iron recycling through heme scavenging, represent an unexplored link to anemia in this population. Methods: In this two-center, cross-sectional analysis of 408 patients treated by prevalent hemodialysis from the prospective Immunity in End-Stage Renal Disease (iESRD) cohort, monocyte subsets were quantified by multicolor flow cytometry. Associations between nonclassical monocyte percentage (%M3) and hemoglobin were evaluated using Spearman rank correlations and multivariable linear regression adjusted for demographics, dialysis vintage, erythropoietin dose, iron parameters, inflammatory markers, and comorbidities. Results: The mean age was 62±12 years, 57% were male, and 45% had diabetes. Patients in the highest %M3 tertile had lower hemoglobin than those in the lowest tertile (10.6±1.2 versus 11.1±1.6 g/dl; P = 0.01). In multivariable regression, each one-tertile higher %M3 was independently associated with 0.29 g/dl lower hemoglobin ( β =−0.29; 95% confidence interval, −0.43 to −0.15; P < 0.001), and this association persisted after further adjustment for BUN and serum creatinine ( β =−0.31; P < 0.001). The association was not attenuated by adjustment for high-sensitivity C-reactive protein, and %M3 showed no correlation with IL-6 or TNF- α . The association was the strongest among diabetic patients (ρ=−0.27; P < 0.001). Conclusions: Nonclassical monocyte expansion is independently associated with anemia severity in patients treated by hemodialysis through an inflammation-independent pathway involving altered iron homeostasis. Monocyte subset profiling may identify patients at risk of refractory anemia.
- Open Access
- 21 January 2026
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
Ferric citrate for iron deficiency anemia in non-dialysis dependent chronic kidney disease: a randomized phase III study
Ferric citrate (FC) can replenish iron stores in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and iron deficiency anemia (IDA). This study evaluated the efficacy and safety of FC (PBF-1681, Panion & BF Biotech Inc.) in NDD-CKD Taiwanese patients. In this double-blind, placebo-controlled, randomized Phase III trial, patients were assigned 1:1 to receive either PBF-1681 or placebo for 16 weeks, followed by an 8-week open-label extension in which all participants received PBF-1681. The starting dose was 2 g/day, with an additional 2 g/day titration based on hemoglobin and serum phosphate levels. A total of 141 patients were randomized to either the PBF-1681 or placebo group. Of these, 114 completed the 16-week randomized period and 106 completed the full 24-week study. The primary endpoint was met, with the PBF-1681 group showing a significantly greater increase in hemoglobin from baseline to Week 16 compared to the placebo group (intergroup difference: 0.62 ± 0.15 g/dL, p < 0.0001). Significant between-group differences were also observed for all secondary and several exploratory endpoints, including the proportion with hemoglobin increase ≥1.0 g/dL, a sustained effect (hemoglobin increase of ≥0.75 g/dL from baseline over any 4-week time period), and changes in iron-related parameters, serum phosphate, intact parathyroid hormone, and fibroblast growth factor 23 levels (all p < 0.05). The most common treatment-related adverse events were gastrointestinal disorders, including diarrhea, discolored feces, abdominal discomfort, constipation, and abdominal pain. PBF-1681 was effective for treating IDA in Taiwanese NDD-CKD patients and had a favorable safety profile.
- 21 January 2026
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
Open AccessFerric citrate for iron deficiency anemia in non-dialysis dependent chronic kidney disease: a randomized phase III study
Ferric citrate (FC) can replenish iron stores in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and iron deficiency anemia (IDA). This study evaluated the efficacy and safety of FC (PBF-1681, Panion & BF Biotech Inc.) in NDD-CKD Taiwanese patients. In this double-blind, placebo-controlled, randomized Phase III trial, patients were assigned 1:1 to receive either PBF-1681 or placebo for 16 weeks, followed by an 8-week open-label extension in which all participants received PBF-1681. The starting dose was 2 g/day, with an additional 2 g/day titration based on hemoglobin and serum phosphate levels. A total of 141 patients were randomized to either the PBF-1681 or placebo group. Of these, 114 completed the 16-week randomized period and 106 completed the full 24-week study. The primary endpoint was met, with the PBF-1681 group showing a significantly greater increase in hemoglobin from baseline to Week 16 compared to the placebo group (intergroup difference: 0.62 ± 0.15 g/dL, p < 0.0001). Significant between-group differences were also observed for all secondary and several exploratory endpoints, including the proportion with hemoglobin increase ≥1.0 g/dL, a sustained effect (hemoglobin increase of ≥0.75 g/dL from baseline over any 4-week time period), and changes in iron-related parameters, serum phosphate, intact parathyroid hormone, and fibroblast growth factor 23 levels (all p < 0.05). The most common treatment-related adverse events were gastrointestinal disorders, including diarrhea, discolored feces, abdominal discomfort, constipation, and abdominal pain. PBF-1681 was effective for treating IDA in Taiwanese NDD-CKD patients and had a favorable safety profile.
- Open Access
- 3 May 2023
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 7 (1) , e44373
Physician Compliance With a Computerized Clinical Decision Support System for Anemia Management of Patients With End-stage Kidney Disease on Hemodialysis: Retrospective Electronic Health Record Observational Study
Background: Previous studies on clinical decision support systems (CDSSs) for the management of renal anemia in patients with end-stage kidney disease undergoing hemodialysis have previously focused solely on the effects of the CDSS. However, the role of physician compliance in the efficacy of the CDSS remains ill-defined. Objective: We aimed to investigate whether physician compliance was an intermediate variable between the CDSS and the management outcomes of renal anemia. Methods: We extracted the electronic health records of patients with end-stage kidney disease on hemodialysis at the Far Eastern Memorial Hospital Hemodialysis Center (FEMHHC) from 2016 to 2020. FEMHHC implemented a rule-based CDSS for the management of renal anemia in 2019. We compared the clinical outcomes of renal anemia between the pre- and post-CDSS periods using random intercept models. Hemoglobin levels of 10 to 12 g/dL were defined as the on-target range. Physician compliance was defined as the concordance of adjustments of the erythropoietin-stimulating agent (ESA) between the CDSS recommendations and the actual physician prescriptions. Results: We included 717 eligible patients on hemodialysis (mean age 62.9, SD 11.6 years; male n=430, 59.9%) with a total of 36,091 hemoglobin measurements (average hemoglobin and on-target rate were 11.1, SD 1.4, g/dL and 59.9%, respectively). The on-target rate decreased from 61.3% (pre-CDSS) to 56.2% (post-CDSS) owing to a high hemoglobin percentage of >12 g/dL (pre: 21.5%; post: 29%). The failure rate (hemoglobin <10 g/dL) decreased from 17.2% (pre-CDSS) to 14.8% (post-CDSS). The average weekly ESA use of 5848 (SD 4211) units per week did not differ between phases. The overall concordance between CDSS recommendations and physician prescriptions was 62.3%. The CDSS concordance increased from 56.2% to 78.6%. In the adjusted random intercept model, the post-CDSS phase showed increased hemoglobin by 0.17 (95% CI 0.14-0.21) g/dL, weekly ESA by 264 (95% CI 158-371) units per week, and 3.4-fold (95% CI 3.1-3.6) increased concordance rate. However, the on-target rate (29%; odds ratio 0.71, 95% CI 0.66-0.75) and failure rate (16%; odds ratio 0.84, 95% CI 0.76-0.92) were reduced. After additional adjustments for concordance in the full models, increased hemoglobin and decreased on-target rate tended toward attenuation (from 0.17 to 0.13 g/dL and 0.71 to 0.73 g/dL, respectively). Increased ESA and decreased failure rate were completely mediated by physician compliance (from 264 to 50 units and 0.84 to 0.97, respectively). Conclusions: Our results confirmed that physician compliance was a complete intermediate factor accounting for the efficacy of the CDSS. The CDSS reduced failure rates of anemia management through physician compliance. Our study highlights the importance of optimizing physician compliance in the design and implementation of CDSSs to improve patient outcomes.
- 3 May 2023
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 7 (1) , e44373
Open AccessPhysician Compliance With a Computerized Clinical Decision Support System for Anemia Management of Patients With End-stage Kidney Disease on Hemodialysis: Retrospective Electronic Health Record Observational Study
Background: Previous studies on clinical decision support systems (CDSSs) for the management of renal anemia in patients with end-stage kidney disease undergoing hemodialysis have previously focused solely on the effects of the CDSS. However, the role of physician compliance in the efficacy of the CDSS remains ill-defined. Objective: We aimed to investigate whether physician compliance was an intermediate variable between the CDSS and the management outcomes of renal anemia. Methods: We extracted the electronic health records of patients with end-stage kidney disease on hemodialysis at the Far Eastern Memorial Hospital Hemodialysis Center (FEMHHC) from 2016 to 2020. FEMHHC implemented a rule-based CDSS for the management of renal anemia in 2019. We compared the clinical outcomes of renal anemia between the pre- and post-CDSS periods using random intercept models. Hemoglobin levels of 10 to 12 g/dL were defined as the on-target range. Physician compliance was defined as the concordance of adjustments of the erythropoietin-stimulating agent (ESA) between the CDSS recommendations and the actual physician prescriptions. Results: We included 717 eligible patients on hemodialysis (mean age 62.9, SD 11.6 years; male n=430, 59.9%) with a total of 36,091 hemoglobin measurements (average hemoglobin and on-target rate were 11.1, SD 1.4, g/dL and 59.9%, respectively). The on-target rate decreased from 61.3% (pre-CDSS) to 56.2% (post-CDSS) owing to a high hemoglobin percentage of >12 g/dL (pre: 21.5%; post: 29%). The failure rate (hemoglobin <10 g/dL) decreased from 17.2% (pre-CDSS) to 14.8% (post-CDSS). The average weekly ESA use of 5848 (SD 4211) units per week did not differ between phases. The overall concordance between CDSS recommendations and physician prescriptions was 62.3%. The CDSS concordance increased from 56.2% to 78.6%. In the adjusted random intercept model, the post-CDSS phase showed increased hemoglobin by 0.17 (95% CI 0.14-0.21) g/dL, weekly ESA by 264 (95% CI 158-371) units per week, and 3.4-fold (95% CI 3.1-3.6) increased concordance rate. However, the on-target rate (29%; odds ratio 0.71, 95% CI 0.66-0.75) and failure rate (16%; odds ratio 0.84, 95% CI 0.76-0.92) were reduced. After additional adjustments for concordance in the full models, increased hemoglobin and decreased on-target rate tended toward attenuation (from 0.17 to 0.13 g/dL and 0.71 to 0.73 g/dL, respectively). Increased ESA and decreased failure rate were completely mediated by physician compliance (from 264 to 50 units and 0.84 to 0.97, respectively). Conclusions: Our results confirmed that physician compliance was a complete intermediate factor accounting for the efficacy of the CDSS. The CDSS reduced failure rates of anemia management through physician compliance. Our study highlights the importance of optimizing physician compliance in the design and implementation of CDSSs to improve patient outcomes.
- 28 February 2023
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 54 (1-2) , 25-34
Extremely Low Dose of Erythropoiesis-Stimulating Agent May Be Associated with Increased Mortality in Hemodialysis Patients
Introduction: Although high-dose erythropoiesis-stimulating agent (ESA) has been shown to increase mortality risk and adverse cardiovascular events in hemodialysis patients, the safety of extremely low-dose ESA is unclear. Methods: We retrospectively analyzed the association between ESA dose and mortality in the monthly dosing range of 0–43,000 U of equivalent epoetin alfa in 304 Taiwan hemodialysis patients by using Cox proportional hazard model and cubic spline model. Results: Compared with mean monthly ESA dose of 15,000–25,000 U (mean ± standard deviation 20,609 ± 2,662 U), monthly ESA dose of less than 15,000 U (mean ± standard deviation 7,413 ± 4,510 U) is associated with increased mortality. Monthly ESA dose of 25,001–43,000 U (mean ± standard deviation 31,160 ± 4,304 U) is not associated with higher mortality risk than monthly ESA dose of 15,000–25,000 U. The results were consistent in Cox proportional hazard models and cubic spline models. Subgroup analyses showed no significant heterogeneities among prespecified subgroups. Conclusions: Extremely low dose of ESA in hemodialysis patients may be associated with increased mortality risk. Future studies are warranted to prove this association.
- 28 February 2023
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 54 (1-2) , 25-34
Extremely Low Dose of Erythropoiesis-Stimulating Agent May Be Associated with Increased Mortality in Hemodialysis Patients
Introduction: Although high-dose erythropoiesis-stimulating agent (ESA) has been shown to increase mortality risk and adverse cardiovascular events in hemodialysis patients, the safety of extremely low-dose ESA is unclear. Methods: We retrospectively analyzed the association between ESA dose and mortality in the monthly dosing range of 0–43,000 U of equivalent epoetin alfa in 304 Taiwan hemodialysis patients by using Cox proportional hazard model and cubic spline model. Results: Compared with mean monthly ESA dose of 15,000–25,000 U (mean ± standard deviation 20,609 ± 2,662 U), monthly ESA dose of less than 15,000 U (mean ± standard deviation 7,413 ± 4,510 U) is associated with increased mortality. Monthly ESA dose of 25,001–43,000 U (mean ± standard deviation 31,160 ± 4,304 U) is not associated with higher mortality risk than monthly ESA dose of 15,000–25,000 U. The results were consistent in Cox proportional hazard models and cubic spline models. Subgroup analyses showed no significant heterogeneities among prespecified subgroups. Conclusions: Extremely low dose of ESA in hemodialysis patients may be associated with increased mortality risk. Future studies are warranted to prove this association.
- Open Access
- 31 January 2023
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 42 (1) , 39-52
Uremic pruritus: pathophysiology, clinical presentation, and treatments
Uremic pruritus is one of the most common and bothersome symptoms in patients with end-stage renal disease. Most patients withuremic pruritus experience a prolonged and relapsing course and significant impairments of quality of life. The pathophysiology of uremicpruritus is not completely understood. A complex interplay among cutaneous biology and the nervous and immune systems hasbeen implicated, with the involvement of various inflammatory mediators, neurotransmitters, and opioids. Uremic pruritus treatmentoutcomes are often unsatisfactory. Clinical trials have mostly been small in scale and have reported inconsistent results. Recent evidenceshows that gabapentinoids, nalfurafine, and difelikefalin are effective for relieving uremic pruritus in hemodialysis patients.This review provides an overview of the epidemiology and proposed mechanisms of uremic pruritus, then highlights the manifestationsof and clinical approach to uremic pruritus. Current evidence regarding treatment options, including topical treatments, treatmentof underlying disease, phototherapy, and systemic treatments, is also outlined. With a better understanding of uremic pruritus,more therapeutic options can be expected in the near future.
- 31 January 2023
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 42 (1) , 39-52
Open AccessUremic pruritus: pathophysiology, clinical presentation, and treatments
Uremic pruritus is one of the most common and bothersome symptoms in patients with end-stage renal disease. Most patients withuremic pruritus experience a prolonged and relapsing course and significant impairments of quality of life. The pathophysiology of uremicpruritus is not completely understood. A complex interplay among cutaneous biology and the nervous and immune systems hasbeen implicated, with the involvement of various inflammatory mediators, neurotransmitters, and opioids. Uremic pruritus treatmentoutcomes are often unsatisfactory. Clinical trials have mostly been small in scale and have reported inconsistent results. Recent evidenceshows that gabapentinoids, nalfurafine, and difelikefalin are effective for relieving uremic pruritus in hemodialysis patients.This review provides an overview of the epidemiology and proposed mechanisms of uremic pruritus, then highlights the manifestationsof and clinical approach to uremic pruritus. Current evidence regarding treatment options, including topical treatments, treatmentof underlying disease, phototherapy, and systemic treatments, is also outlined. With a better understanding of uremic pruritus,more therapeutic options can be expected in the near future.
- Open Access
- 17 November 2022
- Published by JMIR Publications Inc. in JMIR Preprints
Physician Compliance With a Computerized Clinical Decision Support System for Anemia Management of Patients With End-stage Kidney Disease on Hemodialysis: Retrospective Electronic Health Record Observational Study (Preprint)
BACKGROUND Previous studies on clinical decision support systems (CDSSs) for the management of renal anemia in patients with end-stage kidney disease undergoing hemodialysis have previously focused solely on the effects of the CDSS. However, the role of physician compliance in the efficacy of the CDSS remains ill-defined. OBJECTIVE We aimed to investigate whether physician compliance was an intermediate variable between the CDSS and the management outcomes of renal anemia. METHODS We extracted the electronic health records of patients with end-stage kidney disease on hemodialysis at the Far Eastern Memorial Hospital Hemodialysis Center (FEMHHC) from 2016 to 2020. FEMHHC implemented a rule-based CDSS for the management of renal anemia in 2019. We compared the clinical outcomes of renal anemia between the pre- and post-CDSS periods using random intercept models. Hemoglobin levels of 10 to 12 g/dL were defined as the on-target range. Physician compliance was defined as the concordance of adjustments of the erythropoietin-stimulating agent (ESA) between the CDSS recommendations and the actual physician prescriptions. RESULTS We included 717 eligible patients on hemodialysis (mean age 62.9, SD 11.6 years; male n=430, 59.9%) with a total of 36,091 hemoglobin measurements (average hemoglobin and on-target rate were 11.1, SD 1.4, g/dL and 59.9%, respectively). The on-target rate decreased from 61.3% (pre-CDSS) to 56.2% (post-CDSS) owing to a high hemoglobin percentage of >12 g/dL (pre: 21.5%; post: 29%). The failure rate (hemoglobin <10 g/dL) decreased from 17.2% (pre-CDSS) to 14.8% (post-CDSS). The average weekly ESA use of 5848 (SD 4211) units per week did not differ between phases. The overall concordance between CDSS recommendations and physician prescriptions was 62.3%. The CDSS concordance increased from 56.2% to 78.6%. In the adjusted random intercept model, the post-CDSS phase showed increased hemoglobin by 0.17 (95% CI 0.14-0.21) g/dL, weekly ESA by 264 (95% CI 158-371) units per week, and 3.4-fold (95% CI 3.1-3.6) increased concordance rate. However, the on-target rate (29%; odds ratio 0.71, 95% CI 0.66-0.75) and failure rate (16%; odds ratio 0.84, 95% CI 0.76-0.92) were reduced. After additional adjustments for concordance in the full models, increased hemoglobin and decreased on-target rate tended toward attenuation (from 0.17 to 0.13 g/dL and 0.71 to 0.73 g/dL, respectively). Increased ESA and decreased failure rate were completely mediated by physician compliance (from 264 to 50 units and 0.84 to 0.97, respectively). CONCLUSIONS Our results confirmed that physician compliance was a complete intermediate factor accounting for the efficacy of the CDSS. The CDSS reduced failure rates of anemia management through physician compliance. Our study highlights the importance of optimizing physician compliance in the design and implementation of CDSSs to improve patient outcomes.
- 17 November 2022
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessPhysician Compliance With a Computerized Clinical Decision Support System for Anemia Management of Patients With End-stage Kidney Disease on Hemodialysis: Retrospective Electronic Health Record Observational Study (Preprint)
BACKGROUND Previous studies on clinical decision support systems (CDSSs) for the management of renal anemia in patients with end-stage kidney disease undergoing hemodialysis have previously focused solely on the effects of the CDSS. However, the role of physician compliance in the efficacy of the CDSS remains ill-defined. OBJECTIVE We aimed to investigate whether physician compliance was an intermediate variable between the CDSS and the management outcomes of renal anemia. METHODS We extracted the electronic health records of patients with end-stage kidney disease on hemodialysis at the Far Eastern Memorial Hospital Hemodialysis Center (FEMHHC) from 2016 to 2020. FEMHHC implemented a rule-based CDSS for the management of renal anemia in 2019. We compared the clinical outcomes of renal anemia between the pre- and post-CDSS periods using random intercept models. Hemoglobin levels of 10 to 12 g/dL were defined as the on-target range. Physician compliance was defined as the concordance of adjustments of the erythropoietin-stimulating agent (ESA) between the CDSS recommendations and the actual physician prescriptions. RESULTS We included 717 eligible patients on hemodialysis (mean age 62.9, SD 11.6 years; male n=430, 59.9%) with a total of 36,091 hemoglobin measurements (average hemoglobin and on-target rate were 11.1, SD 1.4, g/dL and 59.9%, respectively). The on-target rate decreased from 61.3% (pre-CDSS) to 56.2% (post-CDSS) owing to a high hemoglobin percentage of >12 g/dL (pre: 21.5%; post: 29%). The failure rate (hemoglobin <10 g/dL) decreased from 17.2% (pre-CDSS) to 14.8% (post-CDSS). The average weekly ESA use of 5848 (SD 4211) units per week did not differ between phases. The overall concordance between CDSS recommendations and physician prescriptions was 62.3%. The CDSS concordance increased from 56.2% to 78.6%. In the adjusted random intercept model, the post-CDSS phase showed increased hemoglobin by 0.17 (95% CI 0.14-0.21) g/dL, weekly ESA by 264 (95% CI 158-371) units per week, and 3.4-fold (95% CI 3.1-3.6) increased concordance rate. However, the on-target rate (29%; odds ratio 0.71, 95% CI 0.66-0.75) and failure rate (16%; odds ratio 0.84, 95% CI 0.76-0.92) were reduced. After additional adjustments for concordance in the full models, increased hemoglobin and decreased on-target rate tended toward attenuation (from 0.17 to 0.13 g/dL and 0.71 to 0.73 g/dL, respectively). Increased ESA and decreased failure rate were completely mediated by physician compliance (from 264 to 50 units and 0.84 to 0.97, respectively). CONCLUSIONS Our results confirmed that physician compliance was a complete intermediate factor accounting for the efficacy of the CDSS. The CDSS reduced failure rates of anemia management through physician compliance. Our study highlights the importance of optimizing physician compliance in the design and implementation of CDSSs to improve patient outcomes.
- Open Access
- 1 September 2021
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 1, 100013
Prevalence and Risk Factors for Chronic Kidney Disease in Belize: A Population-based Survey
- 1 September 2021
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 1, 100013
Open AccessPrevalence and Risk Factors for Chronic Kidney Disease in Belize: A Population-based Survey
- 16 June 2021
- Published by Wiley in Hemodialysis International
- Vol. 25 (4) , 541-547
Boiling for 15 minutes improves nutrient profiles in fishes included in the diets of dialysis patients
Introduction Little is known about the effects of boiling on nutrient levels in fishes that have a relatively high phosphorus-to-protein ratio (PPR), which are important sources of omega-3 polyunsaturated fatty acids. We hypothesized that the beneficial effects of boiling for a shorter duration (15 min) on nutrient contents in fishes were similar to those of boiling for a longer duration (30 min), which has been shown to decrease the PPR in meat. Methods The protein, fat, and phosphorus contents and the PPR of three cooked fish species and their corresponding fish broths were chemically analyzed. The effects of boiling on changes in protein, fat, phosphorus, and the PPR was examined by comparing fish that were prepared with usual cooking methods (no boiling), boiled for 15 min, and boiled for 30 min. The nutrients in fish broths that were boiled for 15 min were also compared with those boiled for 30 min. Findings There were no significant differences in the changes in phosphorus, PPR, protein, and fat content in fish and fish broths prepared with the two boiling methods. In the fish boiled for 15 min, the phosphorus content was 24% lower (p = 0.001), and the PPR was 20% lower (p = 0.04) than those in nonboiled fish. Additionally, boiling for 30 min reduced the phosphorus content by 31% (p = 0.001), and the PPR by 27% (p = 0.04) compared to nonboiled fish, but the protein and fat contents were unchanged after both 15 and 30 min of boiling. Discussion The 15- and 30-min boiling methods resulted in a similar reduction in phosphorus and the PPR in fish, with minimal effects on protein and fat. A shorter duration of boiling is recommended to achieve better nutrient profiles in fishes consumed by dialysis patients.
- 16 June 2021
- Published by Wiley in Hemodialysis International
- Vol. 25 (4) , 541-547
Boiling for 15 minutes improves nutrient profiles in fishes included in the diets of dialysis patients
Introduction Little is known about the effects of boiling on nutrient levels in fishes that have a relatively high phosphorus-to-protein ratio (PPR), which are important sources of omega-3 polyunsaturated fatty acids. We hypothesized that the beneficial effects of boiling for a shorter duration (15 min) on nutrient contents in fishes were similar to those of boiling for a longer duration (30 min), which has been shown to decrease the PPR in meat. Methods The protein, fat, and phosphorus contents and the PPR of three cooked fish species and their corresponding fish broths were chemically analyzed. The effects of boiling on changes in protein, fat, phosphorus, and the PPR was examined by comparing fish that were prepared with usual cooking methods (no boiling), boiled for 15 min, and boiled for 30 min. The nutrients in fish broths that were boiled for 15 min were also compared with those boiled for 30 min. Findings There were no significant differences in the changes in phosphorus, PPR, protein, and fat content in fish and fish broths prepared with the two boiling methods. In the fish boiled for 15 min, the phosphorus content was 24% lower (p = 0.001), and the PPR was 20% lower (p = 0.04) than those in nonboiled fish. Additionally, boiling for 30 min reduced the phosphorus content by 31% (p = 0.001), and the PPR by 27% (p = 0.04) compared to nonboiled fish, but the protein and fat contents were unchanged after both 15 and 30 min of boiling. Discussion The 15- and 30-min boiling methods resulted in a similar reduction in phosphorus and the PPR in fish, with minimal effects on protein and fat. A shorter duration of boiling is recommended to achieve better nutrient profiles in fishes consumed by dialysis patients.
- Open Access
- 6 August 2015
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , 12816
Comparative Study of Outcomes among Patients with Polycystic Kidney Disease on Hemodialysis and Peritoneal Dialysis
Polycystic kidney disease (PCKD) is the most common hereditary cause of end-stage renal disease, the complications of which may prevent the choice of peritoneal dialysis (PD). The aim of this study was to explore the effects of dialysis modality on outcomes in patients with PCKD. We extracted a cohort of 1417 adult patients with PCKD initiating long-term dialysis therapy in 1999–2010 from the Taiwan National Health Insurance Research Database, among which 125 patients chose PD. The patients on HD were older and had a higher comorbidity index compared to those on PD. We compared the risks for death, hospitalization and medical expenditures between the patients on PD and propensity-score matched patients on hemodialysis (HD). The overall survival did not differ between the patients on PD and HD. The patients on PD tended to have higher hazard ratios (HR) for the first episode of hospitalization (adjusted HR 1.34 [95% CI, 1.04−1.79]). The annual medical expenses were 10% lower for the patients on PD. PD is an equivalent choice of renal replacement therapy to HD for patients with PCKD in terms of survival. Although the patients on PD had a higher risk for hospitalization, the medical expenditure for PD was 10% lower.
- 6 August 2015
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , 12816
Open AccessComparative Study of Outcomes among Patients with Polycystic Kidney Disease on Hemodialysis and Peritoneal Dialysis
Polycystic kidney disease (PCKD) is the most common hereditary cause of end-stage renal disease, the complications of which may prevent the choice of peritoneal dialysis (PD). The aim of this study was to explore the effects of dialysis modality on outcomes in patients with PCKD. We extracted a cohort of 1417 adult patients with PCKD initiating long-term dialysis therapy in 1999–2010 from the Taiwan National Health Insurance Research Database, among which 125 patients chose PD. The patients on HD were older and had a higher comorbidity index compared to those on PD. We compared the risks for death, hospitalization and medical expenditures between the patients on PD and propensity-score matched patients on hemodialysis (HD). The overall survival did not differ between the patients on PD and HD. The patients on PD tended to have higher hazard ratios (HR) for the first episode of hospitalization (adjusted HR 1.34 [95% CI, 1.04−1.79]). The annual medical expenses were 10% lower for the patients on PD. PD is an equivalent choice of renal replacement therapy to HD for patients with PCKD in terms of survival. Although the patients on PD had a higher risk for hospitalization, the medical expenditure for PD was 10% lower.
- 1 February 2006
- Published by S. Karger AG in Blood Purification
- Vol. 24 (2) , 174-179
Plasma Interleukin-18 Levels in Hemodialysis Patients: Increased by Dialysis Process and Association with Interleukin-6 and Tumor Necrotic Factor-α
Background/Aims: This study investigated changes of interleukin-18 (IL-18) levels before and after dialysis, and the possible association with other pro-inflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). Methods: Plasma IL-18 of healthy controls, and pre- and post-dialysis of uremic patients undergoing hemodialysis (HD) were evaluated by ELISA methodology. Results: Plasma IL-18 levels were significantly increased in patients with maintenance HD (p Conclusion: Plasma IL-18 concentration was significantly higher in HD patients and was significantly elevated by cellulose-based HD processes. Pre-activation of immunologically active cells may contribute to the association between pre-dialysis IL-18 and post-dialysis IL-6 and TNF-α levels.
- 1 February 2006
- Published by S. Karger AG in Blood Purification
- Vol. 24 (2) , 174-179
Plasma Interleukin-18 Levels in Hemodialysis Patients: Increased by Dialysis Process and Association with Interleukin-6 and Tumor Necrotic Factor-α
Background/Aims: This study investigated changes of interleukin-18 (IL-18) levels before and after dialysis, and the possible association with other pro-inflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). Methods: Plasma IL-18 of healthy controls, and pre- and post-dialysis of uremic patients undergoing hemodialysis (HD) were evaluated by ELISA methodology. Results: Plasma IL-18 levels were significantly increased in patients with maintenance HD (p Conclusion: Plasma IL-18 concentration was significantly higher in HD patients and was significantly elevated by cellulose-based HD processes. Pre-activation of immunologically active cells may contribute to the association between pre-dialysis IL-18 and post-dialysis IL-6 and TNF-α levels.